SXLV:SW:SW-SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc) (USD)

ETF | Others |

Last Closing

USD 44.115

Change

+0.04 (+0.08)%

Market Cap

N/A

Volume

1.63K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XLDX:SW Xtrackers LevDAX Daily Swap UC..

-6.00 (-3.57%)

USD 411,075.38B
XNIF:SW Xtrackers Nifty 50 Swap UCITS ..

+0.50 (+0.21%)

USD 292,109.69B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+44.50 (+0.94%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+2.60 (+0.18%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+4.80 (+0.24%)

USD 134,034.85B
SX7EEX:SW iShares EURO STOXX Banks 30-15..

N/A

USD 6,289.31B
TDXPEX:SW iShares TecDAX® UCITS ETF (DE..

N/A

USD 5,933.97B
SMIEX:SW iShares SLI UCITS ETF (DE)

-1.38 (-1.00%)

USD 5,933.96B
DJSXE:SW iShares Core EURO STOXX 50 UCI..

N/A

USD 5,933.96B

ETFs Containing SXLV:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.28% 42% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.28% 42% F 45% F
Trailing 12 Months  
Capital Gain 12.85% 54% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.85% 54% F 57% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.69% 56% F 56% F
Dividend Return 2.69% 56% F 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.09% 57% F 62% D
Risk Adjusted Return 52.79% 56% F 60% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike